Clicky

TIZIANA LIFE SCIENCES LTD(0RP)

Description: Tiziana Life Sciences Ltd, a biotechnology company, focuses on the discovery and development of molecules to treat human diseases in oncology and immunology in the United States. The company's lead product candidate in immunology is Foralumab (TZLS-401), a human anti-CD3 monoclonal antibody (mAb) for the treatment of Crohn's, graft versus host, ulcerative colitis, multiple sclerosis, type-1 diabetes, inflammatory bowel, psoriasis, and rheumatoid arthritis diseases. It also develops Milciclib (TZLS-201), an orally bioavailable small molecule broad spectrum inhibitor of various cyclin-dependent kinases and Src family; and TZLS-501, a fully human mAb targeting the IL-6 receptor for the treatment of inflammatory and oncology indications. Tiziana Life Sciences Ltd was incorporated in 1998 and is headquartered in London, the United Kingdom.


Keywords: Biotechnology Diabetes Immunology Autoimmune Disease Monoclonal Antibodies Arthritis Psoriasis Multiple Sclerosis Ulcerative Colitis Inflammatory Bowel Disease Human Diseases Monoclonal Antibody Therapy Biological Therapy For Inflammatory Bowel Disease Crohn's Rheumatoid Arthritis Diseases

Home Page: www.tizianalifesciences.com

14/15 Conduit Street
London, W1S 2XJ
United Kingdom
Phone:


Officers

Name Title
Mr. Gabriele Marco Antonio Cerrone M.B.A. Founder, Executive Chairman & Interim CEO
Ms. Keeren Shah COO & CFO
Dr. William A. Clementi Ph.D., Pharm.D. Chief Development Officer
Dr. Napoleone Ferrara M.D. Member of Scientific Advisory Board

Exchange: F

Country: DE : Germany

Currency: Euro (€)

Forward PE: 0
Trailing PE: 0
Price-to-Book MRQ: 55.6903
Price-to-Sales TTM: 0
IPO Date:
Fiscal Year End: December
Full Time Employees: 9
Back to stocks